Numbers and indications for growth hormone (GH) therapy
| Code | Diagnosis | Total no. Rx | % males | Age range (median) |
% of total GH Rx |
| Licensed indications (78%) | |||||
| GH deficiency (55%) | |||||
| 1 | Idiopathic growth hormone deficiency | 656 | 68% | 0.3–15.9 (11.5) | 27% |
| 2 | Congenital growth hormone deficiency (e.g. septo-optic dysplasia) | 225 | 61% | 0.7–15.9 (8.4) | 9% |
| 3 | Craniopharyngioma | 91 | 58% | 2.8–15.9 (12.2) | 4% |
| 4 | Other acquired growth hormone deficiency (e.g. post-irradiation) | 347 | 57% | 0.5–15.9 (12.5) | 14% |
| 5 | Turner syndrome | 477 | 0% | 2.4–15.9 (11.3) | 20% |
| 6 | Renal disease | 63 | 68% | 3.0–15.9 (10.3) | 3% |
| Unlicensed indications (22%) | |||||
| 7 | Intrauterine growth retardation | 74 | 67% | 2.3–15.6 (10.7) | 3% |
| 8 | Noonan syndrome | 44 | 68% | 7.0–15.9 (12.2) | 2% |
| 9 | Bony dysplasia | 107 | 55% | 2.7–15.8 (11.5) | 4% |
| 10 | All others | 311 | 61% | 0.5–15.9 (11.9) | 13% |
| Total | 2395 | 100% | |||